NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Syremis Therapeutics

Syremis Therapeutics

Private
Tel AvivHealthcare & Life Scienceshttps://syremis.com/

Last Round

Series A

Dec 18, 2025

Total Funding Raised

$165M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Syremis Therapeutics is a biopharmaceutical company that develops novel medicines for mental health disorders such as schizophrenia, major depressive disorder, and bipolar depression.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverybiotechclinical developmenttherapeutic candidatesneuropsychiatric therapeuticsdrug developmentpreclinical researchbiopharmaintellectual propertyclinical trialssmall-molecule therapeuticslife sciencesR&D pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Syremis Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Syremis Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Syremis Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 18, 2025

Key People

Founding team and executive leadership

Menashe Levy

Co-Founder and CTO

Founding Team

Elisabeth Kogan

CEO And Co-founder At Syremis Therapeutics

Founding Team

Syremis Therapeutics Investors

Notable investors and investment history

Syremis Therapeutics investors
InvestorRounds
Bain Capital Life SciencesSeries A
Pictet GroupSeries A
GVSeries A
QVT FinancialSeries A
Third Rock VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 18, 2025

    $165M Series A round completed.

Syremis Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Syremis Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Syremis Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersTel Aviv
Employee Range37
Year Founded2025
Last FundingDec 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.